GLP-1R agonists’ type 2 diabetes and obesity market to reach $125 billion in 7MM by 2033
According to GlobalData, more than 190 million people currently live with type 2 diabetes and/or obesity in seven major markets, and the numbers will be growing at an annual growth rate (AGR) of 1.35% and 0.57% for type 2 diabetes and obesity, respectively, in the next 10 years.